KR101546111B1 - 신규한 ｓＥＨ 억제제 및 그의 용도 - Google Patents

신규한 ｓＥＨ 억제제 및 그의 용도 Download PDF

Info

Publication number
KR101546111B1
KR101546111B1 KR1020107010233A KR20107010233A KR101546111B1 KR 101546111 B1 KR101546111 B1 KR 101546111B1 KR 1020107010233 A KR1020107010233 A KR 1020107010233A KR 20107010233 A KR20107010233 A KR 20107010233A KR 101546111 B1 KR101546111 B1 KR 101546111B1
Authority
KR
South Korea
Prior art keywords
methyl
amino
phenyl
trifluoromethyl
cyclohexanecarboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107010233A
Other languages
English (en)
Korean (ko)
Other versions
KR20100075619A (ko
Inventor
운 딩
리마 케이. 탈지
조셉 파울 주니어 마리노
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20100075619A publication Critical patent/KR20100075619A/ko
Application granted granted Critical
Publication of KR101546111B1 publication Critical patent/KR101546111B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107010233A 2007-10-11 2008-10-10 신규한 ｓＥＨ 억제제 및 그의 용도 Active KR101546111B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915407P 2007-10-11 2007-10-11
US60/979,154 2007-10-11

Publications (2)

Publication Number Publication Date
KR20100075619A KR20100075619A (ko) 2010-07-02
KR101546111B1 true KR101546111B1 (ko) 2015-08-20

Family

ID=40549589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107010233A Active KR101546111B1 (ko) 2007-10-11 2008-10-10 신규한 ｓＥＨ 억제제 및 그의 용도

Country Status (28)

Country Link
US (2) US8173805B2 (https=)
EP (1) EP2214487B1 (https=)
JP (1) JP5372943B2 (https=)
KR (1) KR101546111B1 (https=)
CN (1) CN101896065B (https=)
AU (1) AU2008310732B2 (https=)
BR (1) BRPI0817542A2 (https=)
CA (1) CA2702265C (https=)
CO (1) CO6270285A2 (https=)
CR (1) CR11423A (https=)
CY (1) CY1114865T1 (https=)
DK (1) DK2214487T3 (https=)
DO (1) DOP2010000101A (https=)
EA (1) EA018414B1 (https=)
ES (1) ES2445444T3 (https=)
HR (1) HRP20140105T1 (https=)
IL (1) IL204889A (https=)
MA (1) MA31761B1 (https=)
MX (1) MX2010003942A (https=)
MY (1) MY157116A (https=)
NZ (1) NZ584471A (https=)
PL (1) PL2214487T3 (https=)
PT (1) PT2214487E (https=)
RS (1) RS53180B (https=)
SI (1) SI2214487T1 (https=)
UA (1) UA107444C2 (https=)
WO (1) WO2009049157A1 (https=)
ZA (1) ZA201002465B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994317B2 (en) 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
WO2009049165A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015104422A1 (en) 2014-01-13 2015-07-16 Basf Se Dihydrothiophene compounds for controlling invertebrate pests
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
WO2016058544A1 (en) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020074549A1 (en) * 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
EP4618985A1 (en) 2022-11-18 2025-09-24 Universitat De Barcelona Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain
WO2026058000A2 (en) 2024-09-13 2026-03-19 Ucl Business Ltd Methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
WO2007106525A1 (en) 2006-03-13 2007-09-20 The Regents Of The University Of California Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420283A (en) * 1993-08-02 1995-05-30 Pfizer Inc. Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
EP1790344B1 (en) * 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US6451814B1 (en) * 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
US20020091133A1 (en) * 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
CA2449486A1 (en) * 2001-06-29 2003-01-09 Boehringer Ingelheim Pharmaceuticals Inc. Methods of using soluble epoxide hydrolase inhibitors
US20030055249A1 (en) 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
EP1505972A2 (en) 2002-05-16 2005-02-16 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
EP1638955A2 (en) * 2003-07-02 2006-03-29 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
WO2006037117A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
EP1831181A2 (en) 2004-12-14 2007-09-12 Vertex Pharmaceuticals Incorporated Pyrimidine inhibitors of erk protein kinase and uses thereof
WO2006121719A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
CA2622754A1 (en) * 2005-10-07 2007-04-19 Boehringer Ingelheim International Gmbh N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
WO2007098352A2 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
US7994317B2 (en) * 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
WO2009049154A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
WO2009049165A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
JPWO2009048154A1 (ja) 2007-10-12 2011-02-24 日本電気株式会社 半導体装置及びその設計方法
WO2009070497A1 (en) 2007-11-28 2009-06-04 Smithkline Beecham Corporation SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE
EP2224928A4 (en) 2007-12-06 2012-02-15 Glaxosmithkline Llc NOVEL INHIBITORS OF SEH AND THEIR USE
WO2009097474A1 (en) 2008-01-30 2009-08-06 Smithkline Beecham Corporation Novel seh inhibitors and their use
EP2240025A4 (en) * 2008-01-30 2012-03-28 Glaxosmithkline Llc NEW SEE INHIBITORS AND THEIR USE
WO2009097476A1 (en) 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
WO2010011917A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
WO2007106525A1 (en) 2006-03-13 2007-09-20 The Regents Of The University Of California Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases

Also Published As

Publication number Publication date
EA018414B1 (ru) 2013-07-30
UA107444C2 (uk) 2015-01-12
CN101896065A (zh) 2010-11-24
ZA201002465B (en) 2010-12-29
ES2445444T3 (es) 2014-03-03
US20100249137A1 (en) 2010-09-30
BRPI0817542A2 (pt) 2014-10-07
EA201070442A1 (ru) 2010-10-29
JP5372943B2 (ja) 2013-12-18
IL204889A0 (en) 2010-11-30
MX2010003942A (es) 2010-04-30
US8173805B2 (en) 2012-05-08
NZ584471A (en) 2012-01-12
HRP20140105T1 (hr) 2014-03-14
AU2008310732B2 (en) 2012-03-08
CA2702265C (en) 2014-12-02
EP2214487B1 (en) 2013-11-27
DOP2010000101A (es) 2010-07-31
CA2702265A1 (en) 2009-04-16
US8212032B2 (en) 2012-07-03
CO6270285A2 (es) 2011-04-20
CN101896065B (zh) 2013-12-18
HK1141211A1 (en) 2010-11-05
RS53180B (sr) 2014-06-30
MA31761B1 (fr) 2010-10-01
CR11423A (es) 2010-06-28
WO2009049157A1 (en) 2009-04-16
CY1114865T1 (el) 2016-12-14
AU2008310732A1 (en) 2009-04-16
SI2214487T1 (sl) 2014-03-31
JP2011500594A (ja) 2011-01-06
PT2214487E (pt) 2014-02-20
EP2214487A1 (en) 2010-08-11
EP2214487A4 (en) 2011-12-21
DK2214487T3 (da) 2014-02-10
PL2214487T3 (pl) 2014-04-30
US20100210656A1 (en) 2010-08-19
KR20100075619A (ko) 2010-07-02
IL204889A (en) 2014-08-31
MY157116A (en) 2016-05-13

Similar Documents

Publication Publication Date Title
KR101546111B1 (ko) 신규한 ｓＥＨ 억제제 및 그의 용도
US20100261743A1 (en) Novel seh inhibitors and their use
US20100210655A1 (en) NOVEL sEH INHIBITORS AND THEIR USE
EP2209376B1 (en) Novel seh inhibitors and their use
US20100324076A1 (en) Novel sEH Inhibitors and their Use
EP2240026A1 (en) NOVEL sEH INHIBITORS AND THEIR USE
EP2240025A1 (en) NOVEL sEH INHIBITORS AND THEIR USE
HK1141211B (en) Novel seh inhibitors and their use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100510

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131008

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150216

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150803

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150813

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150813

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180628

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190624

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20200624

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20200624

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20210723

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20210723

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20220722

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20220722

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20230802

Start annual number: 9

End annual number: 9